Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
20 déc. 2024 06h50 HE
|
Eton Pharmaceuticals
Acquisition bolsters Eton’s commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions ...
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
17 déc. 2024 06h50 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
03 déc. 2024 06h50 HE
|
Eton Pharmaceuticals
Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness...
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
25 nov. 2024 06h50 HE
|
Eton Pharmaceuticals
Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in EuropeStrong strategic fit with Eton’s existing pediatric endocrinology focusAmglidia has been...
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
12 nov. 2024 16h01 HE
|
Eton Pharmaceuticals
Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024...
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
07 nov. 2024 07h00 HE
|
Eton Pharmaceuticals
- Product has patent protection through 2043 -- Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025 - DEER PARK, Ill., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eton...
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
06 nov. 2024 16h30 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
03 oct. 2024 06h30 HE
|
Eton Pharmaceuticals
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions Acquisition to Bolster Eton’s Commercial Pediatric...
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
22 août 2024 16h30 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
08 août 2024 16h01 HE
|
Eton Pharmaceuticals
Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growthNew drug application (NDA) for ET-400 accepted...